THE PREMIUM SERVICE FOR SUBSCRIBERS OF
VALUE-DEPESCHE - August 23rd 2021
Defence
Therapeutics
The vaccination specialist is about to become
popular
The
biotech company is developing vaccines against cancer and Corona. A
vaccine against cancer is expected to be launched in late 2022, and
one against Corona in early 2023. The share is about to become
popular.
Since Biontech and Moderna with
their novel vaccines against viruses, cancer has also come back
into focus. The two companies now also want to develop a vaccine
against cancer and this is boosting their share price. What about
Covid-19 18 months ago? At that time, the two biotech companies
were on the hook to develop a vaccine against the virus and after
announcing these activities, their shares went through the roof
within a few weeks or within two or three months. The mere fact of
"developing a vaccine against Covid" brought the two stocks an
increase in price of + 100 % and more in a short time.
Even before the price surge, Biontech and Moderna were companies
with market values of EUR 5.0 and 10.0 billion
respectively.
As announced a week ago, I have now
unearthed another promising player from that sector for you. Unlike
Biontech and Moderna, however, with valuations in the billions even
before the market launch of a Covid vaccine and the announcement of
its development, this company is only worth EUR 165 million on
the stock market.
"For the time being" is all I can
say. Because my review of Defence Therapeutics has tremendous
prospects! I expect the share price to multiply within the next two
years!
I expect the share price to exceed
10 euros by 2022 at the latest!
The Vancouver biotech company is
working not only on vaccines against infectious diseases and
viruses, but also on a vaccine against cancer and against
Covid-19.
Defence Therapeutics works with a
specially developed platform to potentiate treatment options, for
example against cancer, using ADC antibody-drug conjugates.
Compared to conventional cancer treatments using chemotherapy and
radiation these ADCs have low side effects and act very
specifically against a tumor. ADCs consist of a highly potent toxin
that is coupled with an antibody and, when administered, is
absorbed by a tumor cell which is then killed by the toxin in the
ADC.
The technology developed by Defence
increases the active ingredient of the ADC by a factor of ten in
some cases. The technology has already been successfully tested on
mice and various studies in the approval process with the US Food
and Drug Administration (FDA) are scheduled for the coming months
and quarters.
Well-informed quarters assume that
Defence will launch its first vaccine against cancer by the end of
2022. Defence's platform, together with the corresponding ADC-based
drugs, can be used to develop new active substances relatively
easily and quickly, but also compounds against a wide range of
other diseases.
Industry experts believe that
Defence will have a total of five compounds, for various types of
cancer and infectious diseases, on the market by 2025, i.e. in four
years' time.
That's not all. I have heard from
well-informed sources that the Canadians are working at high speed
to develop a vaccine against Corona. Well-informed sources are 100%
sure that Defence will successfully launch a vaccine on the market.
This should be as early as the first half of 2023, possibly as
early as the beginning of the year.
Conclusion: I see a similar development
coming for Defence as for Biontec and Moderna. In just a few years,
the company could become a billion-dollar corporation. If further
development successes are achieved with the first cancer drug or
the vaccination against Corona, a licensing partnership with a
large pharmaceutical company or even a takeover could be possible.
In the case of a licensing partnership, I believe upfront payments
for Defence of several hundred million dollars are possible as
early as next year. In the event of a takeover, far more could be
paid. In the next two to three years, I expect Defence to have a
market capitalization of more than EUR 1.0 billion euros.
Today it is EUR 165 million. A clear buy for all
risk-loving investors
Risk notice/disclaimer/transparency
notice/other:
All information provided in this newsletter has
been carefully researched and comes from sources we believe to be
reliable. Nevertheless, even the editors may be subject to
misinformation or incorrect information may arise from other
circumstances. All information is therefore provided without
warranty. Liability for lost profits or other financial losses is
therefore excluded. Good results in the past do not guarantee
positive results in the future. This also explicitly applies to any
form of share transactions, in particular option and warrant
transactions: Shares, options and certificates are subject to
various influencing factors. Therefore, it is pointed out that the
investment in shares, options, etc. involves speculative risks
which, depending on the development of the influencing factors, may
lead to losses, in the worst case even to a total
loss.
It is expressly advised against spreading
investment funds over only a few investments or taking out loans
for this purpose. As a precaution, we draw your attention to the
fact that the editorial reviews in VALUE-DEPESCHE cannot replace
individual investment advice from your investment advisor or
investment consultant. The reviews are addressed to all
subscribers/subscribers and readers of our stock letter, who are
very different in their investment behavior and investment
objectives. Therefore, the reviews of this stock letter do not take
into account your personal investment situation in any way. The
investments discussed in VALUE- DEPESCHE are for information purposes
only and do not constitute an invitation to buy or sell
securities.
Members of the editorial team advise investment
products. The securities discussed in VALUE-DEPESCHE or Hot Stock
are part of the investment universe of the product. Members of the
editorial staff, their affiliates or related parties may hold a
long or short position of securities described in VALUE-DEPESCHE
publications and/or options, futures and other derivatives based on
those securities, or other investments related to information
published in the articles. Members of the editorial staff may
advise or have advised the companies mentioned in the articles or
may have a business relationship of some other
kind.
Despite careful control of the content, we assume
no liability for the content of external links. The operators of
the linked pages are solely responsible for their
content.
Subscription
and cancellation
Subscription to Value-Depesche costs EUR 420 (CHF
450) for an annual subscription and EUR 280 (CHF 300) for a
semi-annual subscription. Hot Stock, exclusively for VALUE-DEPESCHE
subscribers, costs EUR 325 (CHF 340). If the service is not
cancelled in writing up to three months before the end of the
subscription period (the easiest way is to send an e-mail to:
leserbrief@value- depesche.ch), the subscription is extended by the last
agreed subscription period of one year or six months at the then
current regular subscription price.
Copyright as well as all publishing rights and
copyrights to "Value-Depesche" and Hot Stock are held by Georg
Pröbstl. Reprints and copies, including excerpts, only with the
written consent of the editors.
Charts courtesy of vwd-group (www.vwd.com)
Data protection: Information on data protection can be
found at http://value-
depesche.ch/content/impress
Defence Therapeutics (QB) (USOTC:DTCFF)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Defence Therapeutics (QB) (USOTC:DTCFF)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
